<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429975</url>
  </required_header>
  <id_info>
    <org_study_id>FIS G03/103</org_study_id>
    <nct_id>NCT00429975</nct_id>
  </id_info>
  <brief_title>Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia</brief_title>
  <official_title>Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Mutua de Terrassa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Mutua de Terrassa</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare levofloxacin vs ceftriaxone impact on the cytokine
      production in patients with pneumococcal pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial alveolar invasion is followed by a compartmentalized inflammatory response. Data
      suggest that some antimicrobials may induce a differential release of cytokines, with the
      potential of either accelerating or down regulating cytokine production.

      The aim of our study was to compare the effects of ceftriaxone compared with levofloxacin on
      cytokine systemic concentrations in patients with pneumococcal pneumonia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2004</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating levels of pro and anti-inflammatory cytokines at 0h, 24, 72 h and 120 h from inclusion</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>the relationship between cytokine expression, clinical variables and severity of disease.</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with an acute febrile respiratory illness accompanied by a new radiographic
             infiltrate consistent with this diagnosis.

          -  and with a confirmed pneumococcal aetiology

        Exclusion Criteria:

          -  age &lt; 18 years,

          -  pneumonia distal to endobronchial obstruction,

          -  pulmonary tuberculosis,

          -  bronchiectasis,

          -  known allergy to B-lactams or fluoroquinolones,

          -  underlying systemic autoimmune disease

          -  immunocompromised states including patients on maintenance oral corticosteroids, HIV
             infection,

          -  pregnancy,

          -  patients that received antimicrobial therapy in the 15 days preceding the current
             episode and those who had received fluoroquinolones in the last month, or non
             steroidal anti-inflammatory therapy in the last two weeks.

          -  Patients with renal failure (serum creatinine &gt; 2 mg / dL),

          -  and patients with a documented pneumococcal pneumonia in the previous 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ESTHER CALBO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Mutua de Terrassa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MONTSERRAT ALSINA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL MUTUA TERRASSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIONA XERCAVINS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Mutua de Terrassa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EVA CUCHI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Mutua de Terrassa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MONICA RODRIGUEZ-CARBALLEIRA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Mutua de Terrassa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JAVIER GARAU, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Mutua de Terrassa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>January 31, 2007</last_update_submitted>
  <last_update_submitted_qc>January 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2007</last_update_posted>
  <keyword>fluorquinolones,</keyword>
  <keyword>b-lactams,</keyword>
  <keyword>immunomodulation.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

